Key clinical message:
Myasthenia gravis is a rare burdensome condition that severely impacts patients’ quality of life—often exacerbated by side effects from long-term immunosuppressive therapy. Although effective therapies exist, more real-world evidence is needed to guide decision-making in refractory cases where treatment discontinuation is considered and can significantly worsen a patient’s condition.